Auto-Immunity Highlights最新文献

{"title":"Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies.","authors":"Danielle Cristiane Baldo,&nbsp;Alessandra Dellavance,&nbsp;Maria Lucia Gomes Ferraz,&nbsp;Luis Eduardo C Andrade","doi":"10.1186/s13317-019-0120-x","DOIUrl":"https://doi.org/10.1186/s13317-019-0120-x","url":null,"abstract":"<p><strong>Background: </strong>Anti-mitochondria autoantibodies (AMA) occur in > 95% primary biliary cholangitis (PBC) patients. Biochemically normal AMA-positive (BN/AMA+) individuals, occasionally noticed by indirect immunofluorescence (IIF) on HEp-2 cells and confirmed in AMA-specific assays, may represent early stages of PBC. The Enhanced Liver Fibrosis (ELF) score is a surrogate marker for liver fibrosis. This prospective study investigated the ELF score in BN/AMA+ individuals and PBC patients, considering autoantibody avidity and serum levels along the years.</p><p><strong>Methods: </strong>327 samples from 35 PBC and 59 BN/AMA+ were prospectively obtained in average 3.83 (range 0.50-7.40) years apart. Samples were tested by IIF on rat-kidney (IIF-AMA), western-blot for AMA (WB-AMA), and ELISA for antibodies against pyruvate-dehydrogenase (PDC-E2), gp210, sp100 and CENP-A/B. Anti-PDC-E2 avidity was determined by 6 M urea-elution ELISA. Alkaline phosphatase (ALP), gamma glutamyl transferase (ɣGT) and ELF score were measured by automated methods.</p><p><strong>Results: </strong>Along the follow-up period BN/AMA+ subjects and PBC patients presented significant increase in serum anti-PDC-E2 (mean 10.45% and 8.86% per year; respectively), anti-PDC-E2 avidity (3.02% and 4.94%/year) and ELF score (3.24% and 2.71%/year). IIF-AMA and ɣGT increased in BN/AMA+ (6.59% and 2.36%) and decreased in PBC (- 4.89%/year and - 3.88%/year). In BN/AMA+ individuals there was positive correlation of ELF with IIF-AMA titer (r = 0.465; p < 0.001) and with anti-PDC-E2 levels (r = 0.239; p < 0.001). Expansion of autoantibody targets along time occurred in 39% BN/AMA+ and 49% PBC patients. The frequency of BN/AMA+ with high probability of having established PBC increased from 7 to 14%.</p><p><strong>Conclusions: </strong>BN/AMA+ individuals present an orchestrated increase in ELF score and humoral autoimmune response over time, indicating an opportunity for early therapeutic intervention and prevention in autoimmunity.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2019-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0120-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiphospholipid syndrome: a case report with an unusual wide spectrum of clinical manifestations.","authors":"Carmela Mazzoccoli,&nbsp;Domenico Comitangelo,&nbsp;Alessia D'Introno,&nbsp;Valeria Mastropierro,&nbsp;Carlo Sabbà,&nbsp;Antonio Perrone","doi":"10.1186/s13317-019-0119-3","DOIUrl":"https://doi.org/10.1186/s13317-019-0119-3","url":null,"abstract":"<p><strong>Background: </strong>Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of venous and/or arterial thrombosis, and the detection of circulating antiphospholipid antibodies. The classification criteria for definite APS are actually met when at least one clinical criterion (thrombosis or pregnancy morbidity) is present in association of one laboratory criterion (LAC, aCL antibody or aβ2GPI antibody present on two or more occasions, at least 12 weeks a part), and thrombosis should be confirmed by objective validated criteria. The average age of primary APS patients has been reported to be about 35-40 years and the disease is more common in women than in men.</p><p><strong>Case presentation: </strong>In this report, we described a rare case of an adult male who presented over a period of 9 years with a wide spectrum of clinical manifestations involving different organs that were not initially diagnosed as APS. Dizziness and syncope were his first clinical symptoms, and a non-bacterial thrombotic endocarditis (NBTE) involving the mitral valve was at first diagnosed. Subsequently, the patient also presented with generalized seizures and subsequent head injury. When the patient was admitted to our clinic with bilateral epistaxis and fever, thrombocytopenia was revealed. Moreover, laboratory examinations showed acute pancreatitis with an increase of levels of inflammation markers.</p><p><strong>Conclusion: </strong>Based on the patient's medical history and all the examination results, it was possible to make a diagnosis of primary APS and, starting from diagnosis of thrombocytopenia, we were allowed to conclude that all of manifestation were epi-phenomena of a unique clinical entity, rather than unrelated diseases. Though APS is one of the most common thrombocytophilias, unfortunately, it is not recognized often enough. The lack of prevention in undiagnosed patients may cause severe complications which can in turn result in the death of those patients.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2019-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0119-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Look granulomatosis with polyangiitis (GPA) straight in the face: missed opportunities leading to a delayed diagnosis.","authors":"N Rolle,&nbsp;M Muruganandam,&nbsp;I Jan,&nbsp;F M Harji,&nbsp;J Harrington,&nbsp;K N Konstantinov","doi":"10.1186/s13317-019-0118-4","DOIUrl":"https://doi.org/10.1186/s13317-019-0118-4","url":null,"abstract":"<p><p>Granulomatosis with polyangiitis (GPA) is a systemic vasculitis with a potential to involve any organ system. It remains an important cause of kidney related morbidity and mortality. Early diagnosis can be difficult and requires high index of suspicion in all patients, but especially in cases with atypical presentation. We report a case with GPA, which was diagnosed only after new and advancing symptoms belied the original diagnosis of bilateral facial palsy and aortic mural thrombus.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2019-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0118-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options.","authors":"Athina Andravizou,&nbsp;Efthimios Dardiotis,&nbsp;Artemios Artemiadis,&nbsp;Maria Sokratous,&nbsp;Vasileios Siokas,&nbsp;Zisis Tsouris,&nbsp;Athina-Maria Aloizou,&nbsp;Ioannis Nikolaidis,&nbsp;Christos Bakirtzis,&nbsp;Georgios Tsivgoulis,&nbsp;Georgia Deretzi,&nbsp;Nikolaos Grigoriadis,&nbsp;Dimitrios P Bogdanos,&nbsp;Georgios M Hadjigeorgiou","doi":"10.1186/s13317-019-0117-5","DOIUrl":"10.1186/s13317-019-0117-5","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system characterized by focal or diffuse inflammation, demyelination, axonal loss and neurodegeneration. Brain atrophy can be seen in the earliest stages of MS, progresses faster compared to healthy adults, and is a reliable predictor of future physical and cognitive disability. In addition, it is widely accepted to be a valid, sensitive and reproducible measure of neurodegeneration in MS. Reducing the rate of brain atrophy has only recently been incorporated as a critical endpoint into the clinical trials of new or emerging disease modifying drugs (DMDs) in MS. With the advent of easily accessible neuroimaging softwares along with the accumulating evidence, clinicians may be able to use brain atrophy measures in their everyday clinical practice to monitor disease course and response to DMDs. In this review, we will describe the different mechanisms contributing to brain atrophy, their clinical relevance on disease presentation and course and the effect of current or emergent DMDs on brain atrophy and neuroprotection.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2019-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0117-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical significance of atypical indirect immunofluorescence patterns on primate cerebellum in paraneoplastic antibody screening.","authors":"Joris Godelaine,&nbsp;Xavier Bossuyt,&nbsp;Koen Poesen","doi":"10.1186/s13317-019-0116-6","DOIUrl":"https://doi.org/10.1186/s13317-019-0116-6","url":null,"abstract":"<p><strong>Purpose: </strong>Screening for paraneoplastic antibodies is often performed by means of indirect immunofluorescence on primate cerebellar slices. However, <i>atypical</i> immunofluorescence patterns, i.e. patterns that are not specifically related to paraneoplastic antibodies, are often reported. The clinical significance of these patterns is not clear. Therefore, the purpose of this study was to determine the significance and diagnostic value-in terms of a paraneoplastic neurological syndrome or other neurological disease being diagnosed in the patient-of such atypical immunofluorescence screening patterns on primate cerebellum.</p><p><strong>Methods: </strong>This study is a retrospective single center study including atypical indirect immunofluorescence screening patterns of patients with a negative or absent typing assay for intraneuronal and anti-amphiphysin paraneoplastic antibodies. Patients with a positive typing assay or without final diagnosis were excluded. Included patients were grouped according to (i) reported immunofluorescence pattern and (ii) established diagnosis, after which contingency table analyses were performed to investigate an interrelation between reported pattern and diagnostic group.</p><p><strong>Results: </strong>In 3.7% of cases, patients with an atypical pattern obtained a final diagnosis of a paraneoplastic neurological syndrome. The presence of atypical patterns was more prominent in patients with epilepsy or peripheral neuropathies (<i>p</i> _{<i>Monte Carlo simulation</i>} = 0.026), without, however, adding any diagnostic information.</p><p><strong>Conclusions: </strong>An atypical indirect immunofluorescence pattern on primate cerebellum in the screening for paraneoplastic antibodies has only very minor relevance with respect to paraneoplastic neurological syndromes or any other neurological disease, recommending clinicians to interpret the results of positive screening assays for such antibodies with care.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2019-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0116-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new M23-based ELISA assay for anti-aquaporin 4 autoantibodies: diagnostic accuracy and clinical correlation.","authors":"Marilina Tampoia,&nbsp;Letizia Abbracciavento,&nbsp;Giuseppina Barberio,&nbsp;Martina Fabris,&nbsp;Nicola Bizzaro","doi":"10.1186/s13317-019-0115-7","DOIUrl":"https://doi.org/10.1186/s13317-019-0115-7","url":null,"abstract":"<p><strong>Purpose: </strong>Although many assays have been developed to detect anti-aquaporin-4 (AQP4) antibodies, most of these assays require sophisticated techniques and are thus only available at specialized laboratories. The aim of this study was to evaluate the analytical and clinical performance of a new commercial enzyme-linked immunosorbent assay (ELISA RSR, AQP4 Ab Version 2) to detect anti-AQP4 antibodies performed on a fully automated system (SkyLAB 752).</p><p><strong>Methods: </strong>Serum samples from 64 patients with neuromyelitis optica spectrum disorders (NMOSD) (including NMO, longitudinally extensive myelitis-LETM, optical neuritis and myelitis) and 27 controls were tested for anti-AQP4 antibodies. All sera were previously tested using an indirect immunofluorescence (IIF) method on primate tissue, as the reference method. Commercial control sera were used to determine within-run, between-day and within-laboratory precision (CLSI guidelines).</p><p><strong>Results: </strong>At a cut-off value of 2.1 U/mL as determined by ROC curves, sensitivity and specificity for NMO were 83.3% and 100%, respectively. The ELISA assay provided 100% concordant results with the reference IIF method. The median concentration of anti-AQP4 antibodies was statistically higher in patients with NMO than in patients with LETM (<i>p </i>= 0.0006) or with other NMOSD and in controls (<i>p </i>< 0.0001). At the concentration of 12.4 and 28.1 U/mL, the within-run, between-day and within-laboratory coefficients of variation (CV) were 3.2% and 3%, 7.6% and 7.4%, and 8.2% and 8.0%, respectively.</p><p><strong>Conclusions: </strong>This new ELISA method performed on a fully automated system, showed high sensitivity and absolute specificity, good CV in precision tests, and provided observer-independent quantitative results.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2019-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0115-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity.","authors":"Ashraf M Okba,&nbsp;Mariam M Amin,&nbsp;Ahmed S Abdelmoaty,&nbsp;Hend E Ebada,&nbsp;Amgad H Kamel,&nbsp;Ahmed S Allam,&nbsp;Omar M Sobhy","doi":"10.1186/s13317-019-0114-8","DOIUrl":"https://doi.org/10.1186/s13317-019-0114-8","url":null,"abstract":"<p><strong>Background: </strong>Apart from endoscopic interventions, readily attainable cost-effective biomarkers for ulcerative colitis (UC) assessment are required. For this purpose, we evaluated differential leucocytic ratio, mainly neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) as simple available indicators of disease activity in patients with ulcerative colitis.</p><p><strong>Methods: </strong>Study conducted on 80 UC patients who were classified into two groups of 40 each according to Mayo score and colonoscopic findings. Group 1 (active UC) and group 2 (inactive UC). Another 40 group-matched healthy participants were enrolled. White blood cell count, NLR, LMR, C-reactive protein, and Erythrocyte sedimentation rate were measured and recorded.</p><p><strong>Results: </strong>Significant elevation of NLR was observed in active UC group compared to inactive UC and controls (2.63 ± 0.43, 1.64 ± 0.25, 1.44 ± 0.19 respectively; p < 0.0001). The optimal NLR cut-off value for active UC was > 1.91, with a sensitivity and a specificity of 90% and 90% respectively. The mean LMRs of active UC was significantly lower compared with inactive UC patients and controls (2.25 ± 0.51, 3.58 ± 0.76, 3.64 ± 0.49 respectively; p < 0.0001). The cut-off value of LMR for determining the disease activity was ≤ 2.88 with a sensitivity of 90% and a specificity of 90%. NLR, LMR, and CRP were found to be significant independent markers for discriminating disease activity (p = 0.000). Besides, NLR was significantly higher in patients with pancolitis and positively correlated with endoscopically severe disease.</p><p><strong>Conclusion: </strong>NLRs and LMRs are simple non-invasive affordable independent markers of disease activity in UC.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2019-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0114-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies exert similar pro-thrombotic effects in peripheral blood monocytes and endothelial cells.","authors":"A Cifù,&nbsp;R Domenis,&nbsp;C Pistis,&nbsp;F Curcio,&nbsp;M Fabris","doi":"10.1186/s13317-019-0113-9","DOIUrl":"https://doi.org/10.1186/s13317-019-0113-9","url":null,"abstract":"<p><strong>Purpose: </strong>The introduction of the anti-phosphatidylserine/prothrombin (aPS/PT) antibodies among the routinely investigated anti-phospholipid (aPL) antibodies led to an improvement in anti-phospholipid syndrome (APS) laboratory diagnostic performance; however, their pathogenic mechanism is still substantially undefined. To support clinical data and future inclusion as possible new criteria antibodies, we designed a head-to-head study to directly compare the procoagulant effects sustained in vitro by aPS/PT to those sustained by anti-β2-glycoprotein I (aβ2GpI) domain 1-specific antibodies.</p><p><strong>Methods: </strong>Blood donors-derived monocytes and endothelial cells (HUVEC) were stimulated with lipopolysaccharides (LPS) alone or in combination with the IgG fractions isolated from the serum of six APS patients, positive only for aβ2GpI or for aPS/PT antibodies. As control, cells were incubated with LPS plus the IgG isolated from blood donors. Tissue factor (TF) mRNA expression was measured after four hours incubation by real-time PCR. Nitric oxide (NO) levels were measured in cells supernatant after 16 h incubation by colorimetric assay.</p><p><strong>Results: </strong>aPS/PT and aβ2GpI IgG antibodies fractions showed comparable ability to enhance LPS-induced TF mRNA expression, either in monocytes and in HUVEC. Compared to LPS alone, we found that NO levels are strongly overproduced in HUVEC treated with LPS plus aβ2GpI and aPS/PT IgG fractions.</p><p><strong>Conclusions: </strong>Our data support the significant and independent role of aPS/PT in the pathogenesis of the thrombotic events in APS patients, possibly adding new light to the therapeutic management of cases characterized by the sole presence of aPS/PT IgG antibodies.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2019-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0113-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of HLA-B27 and Behcet's disease: a systematic review and meta-analysis.","authors":"Alireza Khabbazi,&nbsp;Leila Vahedi,&nbsp;Morteza Ghojazadeh,&nbsp;Fariba Pashazadeh,&nbsp;Amin Khameneh","doi":"10.1186/s13317-019-0112-x","DOIUrl":"https://doi.org/10.1186/s13317-019-0112-x","url":null,"abstract":"<p><strong>Background: </strong>To calculate the genetic impact of the \"HLA-B27\" allele on the risk of Behcet's disease (BD) progression using a systematic review and meta-analysis on case control papers.</p><p><strong>Methods: </strong>A systematic review search was conducted on the MeSH keywords of Behcet's disease, HLAB27 and B27 in PubMed, Scopus, ProQuest, EMBASE, SID, Magiran, IranDoc and IranMedex databases from 1975 to Aug 2017. Data underwent meta-analysis (random effect model) in CMA2 software. Pooled odds ratios with 95% confidence intervals were calculated for each study. The heterogeneity of the articles was measured using the I² index.</p><p><strong>Results: </strong>Twenty two articles met the inclusion criteria for 3939 cases and 6077 controls. The pooled OR of \"HLA-B27\" in BD patients compared with controls was [1.55 (CI 95% 1.01-2.38), P = 0.04]. The OR differ among different countries or geographical areas, focus on domination the European countries. Quality of studies was moderate and heterogeneity was relatively high (I² = 66.9%).</p><p><strong>Conclusions: </strong>There is a significant correlation between HLA-B27 and Behcet's Disease, but it was weak. Environmental and genetic factors might determine which the \"HLA-B27\" alleles manifest Behcet's disease progression. Future researches is required to perform about what factors can do to positively and separately influence Behcet's disease.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2019-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0112-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37249120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of TSLP and IL-33 cytokines in ulcerative colitis.","authors":"Sahar Tahaghoghi-Hajghorbani,&nbsp;Abolghasem Ajami,&nbsp;Saeedeh Ghorbanalipoor,&nbsp;Zahra Hosseini-Khah,&nbsp;Saeid Taghiloo,&nbsp;Peyman Khaje-Enayati,&nbsp;Vahid Hosseini","doi":"10.1186/s13317-019-0110-z","DOIUrl":"https://doi.org/10.1186/s13317-019-0110-z","url":null,"abstract":"<p><strong>Purpose: </strong>Inflammatory bowel disease (IBD) primarily includes ulcerative colitis (UC) and Crohn's disease (CD). Thymic stromal lymphopoietin (TSLP) is a cytokine produced by intestinal epithelial cells (IECs) with immunomodulatory properties that plays an important role in the development of regulatory T cell (Treg) responses and tolerance in the gut. On the other hand, IL-33 has been considered as a cytokine with two different properties, inflammatory and anti-inflammatory functions, the latter may play a protective role against chronic intestinal inflammation. In the present study, we investigated the relative gene expression levels of TSLP and IL-33 molecules in ulcerative colitis.</p><p><strong>Methods: </strong>Patients with clinical symptoms of colitis undergoing a routine diagnostic colonoscopy were included in this study. Biopsy specimens were collected and divided into two parts. One part was fixed and processed for routine histopathological examinations and the other part was stored for RNA extraction. TSLP and IL-33 gene expression were determined using the SYBR Green qRT-PCR.</p><p><strong>Results: </strong>The expression level of TSLP and IL-33 were significantly lower in UC patients compared with the control group. Moreover, the expressions of these cytokines were more down-regulated in severe UC patients compared with mild and moderate ones and the control group. We also showed a positive correlation between low expression of TSLP and IL-33 and the severity of UC disease.</p><p><strong>Conclusions: </strong>In this study, we showed decreased mRNA expression levels of TSLP and IL-33 in UC patients and also a negative correlation between expression of TSLP and IL-33 and severity of UC disease.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"10 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2019-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-019-0110-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37052249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}